公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2015 | IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer | Liu Y.-N.; Chang T.-H.; Tsai M.-F.; SHANG-GIN WU ; TZU-HSIU TSAI ; Chen H.-Y.; SUNG-LIANG YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Oncotarget | 57 | 56 | |
2013 | Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis | Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG | Journal of the National Cancer Institute | 456 | 409 | |
2020 | The impact of smoking on the effectiveness of immune checkpoint inhibitors ??a systematic review and meta-analysis | Lee K.W.C; Lord S.J; Kasherman L; Marschner I; Stockler M; Gralla R; CHIH-HSIN YANG ; Mok T; Lee C.K. | Acta Oncologica | 13 | 12 | |
2015 | Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis | Lee C.K; Wu Y.-L; Ding P.N; Lord S.J; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla R.J; CHIH-HSIN YANG | Journal of Clinical Oncology | 277 | 244 | |
2021 | Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial | Park K.; ?zg?ro?lu, Mustafa; Vansteenkiste J.; Spigel D.; CHIH-HSIN YANG ; Bajars M.; Ruisi M.; Manitz J.; Barlesi F. | Lung Cancer | 1 | 1 | |
2019 | Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides | Hong S.-T; Lin H; Wang C.-S; Chang C.-H; Lin A.M.-Y; CHIH-HSIN YANG ; Lo Y.-L. | Journal of Nanobiotechnology | 35 | 32 | |
2018 | In reply | Gebski V; CHIH-HSIN YANG ; Lee C.K. | JAMA Oncology | 2 | 2 | |
2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
2001 | Inflammation of seborrheic keratoses due to docetaxel treatment [11] | CHIA-YU CHU ; CHIH-HSIN YANG ; HSIEN-CHING CHIU | Acta Dermato-Venereologica | 10 | 7 | |
2010 | Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer | Wu J.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; PAN-CHYR YANG | Lung Cancer | 19 | 18 | |
2020 | The inhibition of Wnt restrain KRASG12V-driven metastasis in non-small-cell lung cancer | Hung P.-S.; Huang M.-H.; Kuo Y.-Y.; CHIH-HSIN YANG | Cancers | 8 | 6 | |
2011 | INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer | Wu Y.-L; Park K; Soo R.A; Sun Y; Tyroller K; Wages D; Ely G; CHIH-HSIN YANG ; Mok T. | BMC Cancer | 79 | 61 | |
2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A; Reungwetwattana, Thanyanan; CHIH-HSIN YANG ; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun; Lee, Ki Hyeong; Pang, Yong-Kek; Zimina, Anastasia; Fong, Chin Heng; Poddubskaya, Elena; Sezer, Ahmet; How, Soon Hin; Danchaivijitr, Pongwut; Kim, YuKyung; Lim, Yeji; An, Taewon; Lee, Hana; Byun, Hae Mi; Zaric, Bojan | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 11 | 1 | |
2016 | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts | Ramalingam S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. | Journal of Thoracic Oncology | 66 | 57 | |
2016 | LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results | CHIH-HSIN YANG ; Ramalingam S.S; Jänne P.A; Cantarini M; Mitsudomi T. | Journal of Thoracic Oncology | 89 | 82 | |
2022 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer | Tsuboi, Masahiro; Goldman, Jonathan W; Wu, Yi-Long; Johnson, Melissa L; Paz-Ares, Luis; CHIH-HSIN YANG ; Besse, Benjamin; Su, Weiji; Chao, Bo H; Drilon, Alexander | Future oncology (London, England) | 9 | 7 | |
1995 | Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes | KUN-HUEI YEH ; Lin M. T.; JIH-LUH TANG ; CHIH-HSIN YANG ; WOEI TSAY ; YAO-CHANG CHEN | British Journal of Haematology | 19 | 14 | |
2021 | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC | Awad M.M.; Gadgeel S.M.; Borghaei H.; Patnaik A.; CHIH-HSIN YANG ; Powell S.F.; Gentzler R.D.; Martins R.G.; Stevenson J.P.; Altan M.; Jalal S.I.; Panwalkar A.; Gubens M.; Sequist L.V.; Saraf S.; Zhao B.; Piperdi B.; Langer C.J. | Journal of Thoracic Oncology | 94 | 77 | |
2021 | Lung Cancer in Republic of China | Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG ; BIN-CHI LIAO ; Hsia T.-C.; Chen Y.-M. | Journal of Thoracic Oncology | 33 | 26 | |
2008 | Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response | Wu J.-Y.; SHANG-GIN WU ; CHIH-HSIN YANG ; Gow C.-H.; YIH-LEONG CHANG ; CHONG-JEN YU ; Shin J.-Y.; PAN-CHYR YANG | Clinical Cancer Research | 278 | 250 | |